Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Before the recent approvement of ranibizumab (Lucentis) for the treatment of neovascular age-related macular degeneration (AMD), bevazicumab (Avastin) had been successfully used as an off-label treatment for this condition.1 As a consequence, in daily practice we are confronted with a large number of patients having received Avastin injections in the past, now facing a recurrence of the disease and therefore requiring additional injections.2 This leaves the ophthalmologist in a medical dilemma: should one continue with the off-label drug Avastin or switch to Lucentis? From a clinical point of view and disregarding the legal aspects of continuing …
Competing interests: None.